



Contacts:

David Waldman or Justyna Gudaszewska
Crescendo Communications Europe Sp. z.o.o
Email: mmd@crescendo-ir.com
Tel: (+48 71) 79 11 551

Milestone Medical Inc. Submits Initial Results of Clinical Trial to Premier European Pain Management Society for Publication

CompuFlo technology as safe and effective as standard of medical practice in the epidural space identification when compared to Loss of Resistance Technique assisted with the radiological X-ray based fluoroscopy

LIVINGSTON, NJ, November 18, 2015 -- Milestone Medical Inc. (WAR: MMD), today announced that it has submitted initial results of the Company's prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure to a prestigious European pain management society in advance of this organization's annual meeting in 2016.

Milestone Medical, Inc. designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space as part of the acute and chronic pain management.

Successful and safe performance of epidural anesthesia or epidural injections relies on correct identification of the epidural space. Preliminary study results suggested that the non-invasive CompuFlo® technology was as accurate and effective as the current standard of medical practice, loss of resistance technique assisted with the radiological X-ray based fluoroscopy in objectively and accurately identifying the epidural space. Data further suggested that the CompuFlo® technology has the potential to successfully replace current standard of medical care while eliminating exposure to radiation.

Leonard Osser, Chief Executive Officer of Milestone Medical, added, "We are pleased to have submitted initial results of this prospective, open labeled, clinical trial to one of the most prestigious European pain management societies. We believe that the ability of the CompuFlo® technology to confirm the epidural space in real time as opposed to the current 2 step approach, will provide significant advantages for anesthesiologists and patients. The current process requires advancing an epidural needle via loss of resistance technique and then confirming the space by injecting contrast and visualizing it under X-ray fluoroscopy. Along with other benefits, our process has the potential to significantly reduce cost and avoid radiation exposure for the patients and medical practitioners."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across the European Union. For more information please visit www.medicalmilestone.com.